Vaccine-based immunotherapy can increase the overall survival of patients with advanced prostate cancer.
However, the efficacy of vaccine-elicited anticancer immune responses is heavily influenced by the physical, nutritional, and psychological status of the patient. Given their importance, these parameters should be carefully considered for the design of future clinical trials testing this immunotherapeutic paradigm in prostate cancer patients.
Written by:
McArdle SE, Pockley AG, Gibson GR, Rees RC. Are you the author?
The John van Geest Cancer Research Centre; Nottingham Trent University; Nottingham, UK; University of Reading; Reading, UK.
Reference: Oncoimmunology. 2014 Feb 14;3:e28049.
PubMed Abstract
PMID: 25340006